Effect of VIP on the balance between cytokines and master regulators of activated helper T cells

Immunology and Cell Biology

Volumn 90, Issue 2, 2012, Pages 178-186

  Jimeno, Rebeca ^a   Leceta, Javier ^a   Martínez, Carmen ^a   Gutiérrez Cãas, Irene ^a   Pérez García, Selene ^a   Carrión, Mar ^a   Gomariz, Rosa P ^a   Juarranz, Yasmina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

master regulators; signature cytokines; T cell subsets; vasoactive intestinal peptide

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 4; INTERLEUKIN 9; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HELPER CELL; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; MOUSE; NONHUMAN; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REGULATORY T LYMPHOCYTE TH1 BALANCE; REGULATORY T LYMPHOCYTE TH17 BALANCE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH1 TH17 BALANCE; TH1 TH2 BALANCE; TH17 CELL; TH2 CELL; TH2 TH9 BALANCE;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; INTERFERON-GAMMA; INTERLEUKIN-4; INTERLEUKIN-9; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; RNA, MESSENGER; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH1-TH2 BALANCE; TH17 CELLS; TH2 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

MUS;

EID: 84857033226     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.23     Document Type: Article

References (50)

1. Betteli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of Th17 cells. Nature 2008; 453: 1051-1057. (Pubitemid 351871737)
2. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 198; 97: 145-173.
3. Murphy KM, Stockinger B. Effector T cell plasticity: flexibility in the face of changing circumstances. Nat Immunol 2010; 11: 674-680.
4. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10: 490-500.
5. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH17, TH1 and TH2 cells. Nat Immunol 2009; 10: 864-871.
6. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J et al. Transforming growth factor-'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2009; 9: 1341-1346.
7. Wan YY. Multi-tasking of helper T cells. Immunology 2010; 130: 166-171.
8. Zhu J, Paul WE. CD4T cells: fates, functions, and faults. Blood 2008; 112: 1557-1569.
9. O'Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity helper CD4+ T cells. Science 2010; 327: 1098-1102.
10. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 2010; 20: 4-12.
11. Wei L, Vahedi G, Sun HW, Watford WT, Takatori H, Ramos HL et al. Discrete roles of STAT4 and STAT6 transcription factors in tuning epigenetic modifications and transcription during T helper cell differentiation. Immunity 2010; 32: 840-851.
12. Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther 2009; 121: 294-316.
13. Gomariz RP, Mart?́nez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001; 7: 89-111. (Pubitemid 32409709)
14. Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Mart?́nez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann NY Acad Sci 2006; 1070: 51-74. (Pubitemid 44126625)
15. Gonzalez-Rey E, Anderson P, Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis 2007; 66: iii70-iii76. (Pubitemid 350032639)
16. Laburthe M, Couvineau A, Tan YV. Class II G protein coupled-receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007; 28: 1631-1639. (Pubitemid 47371033)
17. Langer I, Robberecht P. Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors. Biochem Soc Trans 2007; 35: 724-738.
18. Smalley SG, Barrow PA, Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol 2009; 157: 225-234.
19. Arranz A, Abad A, Juarranz Y, Leceta J, Mart?́nez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15: 46-53.
20. Calafat M, Larocca L, Roca V, Hauk V, Pregi N, Nesse A et al. Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 2009; 11: R53.
21. Delgado M, Abad C, Mart?́nez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7: 563-568. (Pubitemid 32448323)
22. Lodde BM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65: 195-200. (Pubitemid 43131993)
23. Deng S, Xi Y, Wang H, Hao J, Niu X, Li W et al. Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis. Cell Immunol 2010; 265: 105-110.
24. Gutié rrez-Cañ as I, Juarranz Y, Santiago B, Mart?́nez C, Gomariz RP, Pablos JL et al. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 2008; 22: 312-317. (Pubitemid 351172708)
25. Leceta J, Gomariz RP, Mart?́nez C, Carrión M, Arranz A, Juarranz Y. Vasoactive intestinal peptide (VIP) regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 2007; 14: 134-138. (Pubitemid 350249107)
26. Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal peptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006; 26: 430-437. (Pubitemid 44440176)
27. Pozo D, Anderson P, González-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009; 183: 4346-4359.
28. Roca V, Calafat M, Larocca L, Ramhorst R, Farina M, Franchi AM et al. Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction 2009; 138: 733-742.
29. Yadav M, Rosenbaum J, Goetzl EJ. Cutting edge: vasoactive intestional peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008; 180: 2772-2776.
30. Jimeno R, Gomariz RP, Gutié rrez-Cañ as I, Mart?́nez C, Juarranz Y, Leceta J. New insights into the role of VIP on the ratio of T cell subsets during development of autoimmune diabetes. Immunol Cell Biol 2010; 88: 734-745.
31. Juarranz Y, Abad C, Mart?́nez C, Arranz A, Gutié rrez-Cañ as I, Rossignoli F et al. Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1034-R1045.
32. Korn T, Betelli E, Oukka M, Kuchroo K. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27: 485-517.
33. Abad C, Mart?́nez C, Juarranz Y, Arranz A, Leceta J, Delgado M et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003; 124: 961-971. (Pubitemid 36389799)
34. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4T cell populations. Ann Rev Immunol 2010; 28: 445-489.
35. Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B et al. Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; doi 10.1172/JCI37865.
36. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39: 216-224.
37. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA et al. IL-4 inhibits TGFinduced Foxp3+ T cells and together with TGFb, generated IL-9+ IL10+ Foxp3- effector cells. Nat Immunol 2008; 9: 1347-1355.
38. Malek TR, Castro I. Interleukin-2 receptor signalling: at the interface between tolerance and immunity. Immunity 2010; 33: 153-165.
39. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
40. Yoshimura A, Wakabashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGFb. J Biochem 2010; 147: 781-792.
41. Zeng WP, Chang C, Lai JJ. Immune suppressive activity and lack of T helper differentiation are differentially regulated in natural regulatory T cells. J Immunol 2009; 183: 3583-3590.
42. Boudard F, Bastide M. Inhibition of mouse T-cell proliferation by CGRP and VIP: effects of these neuropeptides on IL-2 production and cAMP synthesis. J Neurosci Res 1991; 29: 29-41.
43. Teresi S, Boudard F, Bastide M. Effect of calcitonin gene-related peptide and vasoactive intestinal peptide on murine CD4 and CD8T cell proliferation. Immunol Lett 1996; 50: 105-113. (Pubitemid 26180007)
44. Abad C, Juarranz Y, Mart?́nez C, Arranz A, Rosignoli F, Garc?́a-Gómez M et al. cDNA array analysis of cytokines, chemokines and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 2005; 11: 674-684. (Pubitemid 40961082)
45. Delgado M, Muñ oz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol 1999; 96: 167-181. (Pubitemid 29234491)
46. Lu J, Zheng MH, Yan J, Chen YP, Pan JP. Effects of vasoactive intestinal peptide on phenotypic and functional maduration of dendritic cells. Int Immunopharmacol 2008; 8: 1449-1454.
47. Dorsam ST, Vomhof-Dekrey E, Hermann RJ, Haring JS, Van der Steen T, Wilkerson E et al. Identification of the early VIP-regulated transcriptome and its associated interactome in resting and activated murine CD4T cells. Mol Immunol 2010; 47: 1181-1194.
48. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009; 30: 616-625.
49. Delgado M, Mart?́nez C, Johnson MC, Gomariz RP, Ganea D. Differential expression of vasoactive intestinal receptor 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol 1996; 87: 5152-5161.
50. Lara-Marquez ML, O'Dorisio MS, O'Dorisio TM, Shah MH, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cell. J Immunol 2001; 166: 2522-2530. (Pubitemid 32173489)